Findings of the prespecified analysis of the trial, published in The Lancet, suggest that semaglutide and possibly other glucagon-like peptide-1 receptor agonists (GLP-1Ras) should be reconceptualised as disease-modifying treatments rather than solely medications for glycaemic control or weight loss, the studys authors have suggested
Start GLP-1 therapy the easy way with the NiceRx Microdose GLP-1 Program
[PUBMED Abstract] Binni F, Antigoni I, De Simone P, et al.: Novel and recurrent p14 mutations in Italian familial melanoma
Lifestyle Factors and Metabolic Health Optimization Tirzepatide works most effectively when combined with consistent physical activity (150+ min/week moderate intensity), adequate protein intake (0.81.2 g/kg body weight), and sleep optimization
Synergistic effects of applying static magnetic fields and diazepam to improve EEG abnormalities in the pilocarpine epilepsy rat model